Workflow
Tavistock to buy 76.59% stake in financial advisory firm Lifetime
Yahoo Finance· 2025-09-15 12:17
Private equity firm Tavistock has agreed to purchase a 76.59% stake in UK-based financial advisory company Lifetime. The deal is valued at around £5.95m, according to FT Adviser. Lifetime CEO Ian Dickinson will retain the remaining stake in the business. Lifetime is known for its "hybrid model" of services that includes financial advice, mortgages, investments, pensions, estate planning, savings, and protection. The firm also offers financial wellbeing solutions, featuring tools such as the Lifetime Hu ...
4 Tech Stocks That Look Overpriced — Do You Own One? - Hewlett Packard (NYSE:HPE), Docusign (NASDAQ:DOCU)
Benzinga· 2025-09-15 12:16
A sharp week-on-week decline in value percentile rankings has hit several prominent technology companies, suggesting market perceptions around relative worth and fundamental strength are shifting.What Does Value Ranking Mean?Using percentile-based metrics, the Benzinga Edge Stock Ranking‘s value metric compares each company’s market price with core fundamentals such as assets, earnings, sales, and operating performance.4 Overvalued Tech Stocks Deteriorating In Value RankingsThis week, Hewlett Packard Enterp ...
Mild price pressure on gold amid profit taking
KITCO· 2025-09-15 12:16
Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York. As a journalist, he has covered every futures market traded in the U.S., at one time or another. Jim is the proprietor of the "Jim Wyckoff on the Markets" analytical, educational and trading advisory service. Jim also worked as a ...
INVESTOR ALERT: Berger Montague Advises Fiserv, Inc. (NYSE: FI) Investors to Inquire About a Securities Fraud Class Action by September 22, 2025
Prnewswire· 2025-09-15 12:16
Accessibility StatementSkip Navigation Investor Deadline: Investors who purchased or acquired Fiserv securities during the Class Period may, no later than September 22, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE. Fiserv is headquartered in Brookfield, Wisconsin, and is a leading provider of financial services technology, including payment and processing systems used by institutions worldwide. The lawsuit alleges that Fiserv and certain exe ...
MEG Energy urges investors to reject Strathcona's sweetened bid, backs Cenovus deal
Reuters· 2025-09-15 12:16
Canadian oil sands producer MEG Energy on Monday urged shareholders to reject the sweetened takeover bid from its majority stakeholder Strathcona Resources , and reaffirmed support for sale to Cenovus... ...
California Resources to merge with Berry Corp in $717 million deal
Reuters· 2025-09-15 12:16
Group 1 - California Resources is acquiring Berry Corp in an all-stock deal valued at approximately $717 million, including debt [1] - The acquisition reflects California Resources' strategy to expand its portfolio in the oil production sector [1] - The deal signifies a consolidation trend within the U.S. energy industry, particularly among smaller oil producers [1] Group 2 - The transaction highlights the ongoing interest in mergers and acquisitions as companies seek to enhance operational efficiencies and market presence [1] - The valuation of Berry Corp at $717 million indicates a significant investment in the current energy market [1] - This acquisition may lead to potential synergies and cost savings for California Resources, enhancing its competitive position [1]
Wall Street Has a Mixed Opinion on Ambev S.A (ABEV), Here’s Why
Yahoo Finance· 2025-09-15 12:15
Ambev S.A (NYSE:ABEV) is one of the Best Low Cost Stocks to Buy According to Analysts. Wall Street has a mixed opinion on Ambev S.A (NYSE:ABEV) after the company missed revenue estimates for its fiscal second quarter of 2025. The company delivered $3.59 billion in revenue, which grew around 2.65% year-over-year but fell short of expectations by $250.95 million. The EPS of $0.03 stayed in line with the consensus. Management noted that its total organic volumes decreased by 4.5% year-over-year due to indust ...
ONEOK (OKE) Announces a New Gas Pipeline
Yahoo Finance· 2025-09-15 12:15
ONEOK, Inc. (NYSE:OKE) is one of the Best Low Cost Stocks to Buy According to Analysts. On August 25, ONEOK, Inc. (NYSE:OKE), along with WhiteWater, MPLX, and Enbridge, announced a new natural gas pipeline called the Eiger Express. The pipeline is expected to transport gas from the Permian Basin in West Texas to the Houston area and Corpus Christi markets in Texas. It is about 450 miles long and 42 inches in diameter, and can carry up to 2.5 billion cubic feet of natural gas per day. Management noted th ...
Deep Blue to Acquire Environmental Disposal Systems from Diamondback Energy (FANG)
Yahoo Finance· 2025-09-15 12:15
Diamondback Energy, Inc. (NASDAQ:FANG) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 2, the company announced that Deep Blue will acquire Environmental Disposal Systems, LLC from Diamondback in a deal valued at $750 million. The acquisition is expected to nearly double Deep Blue’s size, and as part of the agreement, Diamondback Energy, Inc. (NASDAQ:FANG) renewed a 15-year agreement for produced and supplied water within a 12-county area in the Midland Basin. Diamondback wil ...
Leerink Partners Maintains a Buy Rating on Sanofi (SNY)
Yahoo Finance· 2025-09-15 12:15
Sanofi (NASDAQ:SNY) is one of the Best Low Cost Stocks to Buy According to Analysts. On September 6, Leerink Partners analyst David Risinger maintained a Buy rating on Sanofi (NASDAQ:SNY) without a price target. The analyst acknowledged the challenges faced by the company with Amlitelimab in its Phase 3 trial, as the results did not meet the high benchmark set by Dupixent. However, Risinger noted that Amlitelimab can still achieve its primary and secondary endpoints, showing promise as a second-line treat ...